In metastatic melanoma it is known that both anti-CTLA4 and anti-PDL1 treatment failures are driven by a tumor microenvironment full of TNFR2+ Tregs, suggesting that TNFR2 could be a similar escape pathway for the lost effectiveness on current therapies in SS [37]. Here, CTLA4 is linked to metastatic melanoma.